Business
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for
About this update from Biomark Diagnostics, Inc.
[{"type":"text","content":"Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay","length":120,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for the imminent commercial launch of its lung cancer assay. This critical advancement in its operational capabilities solidifies the expansion of its diagnostic and research services and positions the Company as a central hub for innovation, high-throughput diagnostics, and collaborative ventures.","length":698,"tagName":"p"},{"type":"text","content":"Accelerating Commercialization and Market Entry for Life-Saving DiagnosticsThe newly acquired state-of-the-art laboratory equipment is aligned with BioMark's commercialization strategy. This enhanced capacity directly addresses the escalating global demand for non-invasive liquid biopsy diagnostics and, crucially, prepares the Company for the widespread clinical deployment of its metabolomic-based lung cancer diagnostic assay. The expansion also facilitates the provision of advanced diagnostic analytical molecular services to international clients and significantly expands its research capabilities to accommodate the growing needs of metabolomics from pharmaceutical and biotechnology companies. Furthermore, this initiative supports the accelerated rollout of multiple new assays, aligning with the company's laboratory certification and accreditation roadmap.","length":878,"tagName":"p"},{"type":"text","content":""Our enhanced laboratory capacity underscores BioMark's unwavering commitment to clinical excellence, innovation, and accessibility," stated Jean-Francois Haince, CSO and GM of BioMark Diagnostic Solutions. "Once certified, this laboratory will serve as a pivotal engine for commercialization, revenue generation, strategic partnerships, and the widespread clinical deployment of our metabolomic-based diagnostic assays."","length":4...